Dana-Farber Cancer Institute

Cancer survivors with elevated levels of NT-proBNP have a higher risk of death, according to an analysis conducted by Dana-Farber Cancer Institute.

Dana-Farber Cancer Institute researchers are the recipients of the Outstanding Investigator Award from the NCI, part of the National Institutes of Health.

More than 125 Dana-Farber affiliated doctors have been included in Boston magazine's annual "Top Doctors" guide.

To understand how fertility concerns affect breast cancer treatment decisions, researchers analyzed data from the Young and Strong study.

Blood test uses cell-free DNA methylation to quantify tumor burden and distinguish neuroendocrine prostate cancer from prostate adenocarcinoma.

Belzutifan, a HIF-2α inhibitor, has been approved by the FDA for the treatment of patients with advanced kidney cancer previously treated with immune checkpoint inhibitors and antiangiogenic therapies.

Researchers at Dana-Farber Cancer Institute found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

Researchers at Dana-Farber Cancer Institute have found that the diversity of T cells in peripheral blood declines with age in patients with breast cancer and, in younger patients, is lower in those diagnosed with metastatic disease than with ductal carcinoma in situ.

Dana-Farber Cancer Institute is launching a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and to prevent cancer from arising in individuals at increased risk for the disease.

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 46th annual San Antonio Breast Cancer Symposium, December 5–9, 2023.

The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.

A drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results in a clinical trial involving patients with advanced neuroendocrine tumors, according to a study led by Dana-Farber Cancer Institute investigators.

In a new paper in JCO Oncology Practice, bioethics researchers at Dana-Farber Cancer Institute call on medical societies, government leaders, clinicians, and researchers to work together to ensure AI-driven healthcare preserves patient autonomy and respects human dignity.

Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma, the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.

Dana-Farber Cancer Institute, a Harvard Medical School affiliated teaching hospital and one of the world's leading cancer treatment and oncology research institutions, and Oncoclínicas & Co, the largest group dedicated to cancer in Latin America, announce the expansion of their collaboration with the opening of the first Oncoclínicas Cancer Center as an International Collaborative Member of Dana-Farber Cancer Institute.

Bradley Bernstein, MD, PhD, Chair of Cancer Biology at Dana-Farber Cancer Institute, has been elected to the National Academy of Medicine.

Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology Congress 2023 in Madrid, Spain.

Loss of the “housekeeping” gene methylthioadenosine phosphorylase, or MTAP, is a common event in cancer.

New research from Dana-Farber Cancer Institute researcher Cigall Kadoch, PhD, along with colleagues at Princeton University and Washington University in St. Louis, reveals a key role for intrinsically disordered proteins known as IDRs that are implicated in a wide range of human diseases, from cancer to neurodegeneration

A team of Dana-Farber researchers has identified a potential new way to assess clinically valuable features of clear cell renal cell carcinoma, a form of kidney cancer, using image processing with deep learning.

A new agent that subverts myeloma cells from within while also subjecting them to an immune system attack produced impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies

Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center announced plans for a comprehensive new collaboration designed to advance the future of cancer care and build the region’s only independent, free-standing inpatient hospital for adult cancer patients.

Researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas– incurable brain tumors– can arise due to changes in the epigenome.

Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.

Patients with depression and/or anxiety prior to a diagnosis of diffuse large B-cell lymphoma had shorter survival times than patients without a mental health diagnosis.

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers.

People living with HIV remain at higher risk than people living without HIV for developing various cancers that can be treated with immune checkpoint inhibitors.

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

A new study published today in the New England Journal of Medicine found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur.

In the open-label phase 2 LITESPARK-003 study, led by Dana-Farber Cancer Institute’s Toni Choueiri, MD, researchers investigated for the first time the combination of cabozantinib, a VEGF TKI, plus belzutifan, a HIF-2α inhibitor.